Capricor Therapeutics Inc. (CAPR)
Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains?
Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Capricor Therapeutics, Inc. (CAPR) Q2 2024 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Linda Marban – Chief Executive Officer AJ Bergmann – Chief Financial Officer Conference Call Participants Joseph Pantginis – H.C. Wainwright Leland Gershell – Oppenheimer Aydin Huseynov – Ladenburg Rick Miller – Cantor Operator Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics Second Quarter 2024 Earnings Call.
Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates
Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.29 per share a year ago.
Capricor (CAPR) Advances in DMD Therapy With Positive Study Data
Capricor (CAPR) anticipates announcing top-line results from the Phase 3 HOPE-3 pivotal trial by the fourth quarter of 2024.
